HUTCHMED
About: HUTCHMED (China) Ltd is an innovative biopharmaceutical company engaged in the discovery, global development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. The company operates in two reportable segments Oncology/Immunology, and Other Ventures.
Employees: 1,990
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
43% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 7
5% more funds holding
Funds holding: 64 [Q3] → 67 (+3) [Q4]
0.05% less ownership
Funds ownership: 0.83% [Q3] → 0.78% (-0.05%) [Q4]
29% less repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 24
30% less capital invested
Capital invested by funds: $140M [Q3] → $98.1M (-$41.6M) [Q4]
68% less call options, than puts
Call options by funds: $118K | Put options by funds: $365K
Research analyst outlook
We haven’t received any recent analyst ratings for HCM.
Financial journalist opinion
Based on 10 articles about HCM published over the past 30 days









